VYNE Therapeutics Inc.
VYNEDrugs in Pipeline
17
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
5mg Serlopitant Tablets
Pruritus
FMX101
Acne Vulgaris
FMX103 1.5%
Papulopustular Rosacea
FMX-101, 4% minocycline foam
Acne Vulgaris
Vehicle Foam
Acne Vulgaris
FMX103 minocycline foam 1.5%
Facial Papulopustular Rosacea
serlopitant
Prurigo Nodularis
5 mg Serlopitant Tablets
Pruritus
VYN201 Gel
Non-segmental Vitiligo
FMX114
Atopic Dermatitis
Serlopitant High Dose
Pruritus
FMX-103 1.5%
Rosacea
3% Minocycline Foam
Acne Vulgaris
FDX104 (4% Doxycycline)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
VPD-737
Chronic Pruritus
MK0594
Urinary Incontinence
Topical Minocycline Foam FXFM244
Acne Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
5mg Serlopitant Tablets | Phase 3 | Pruritus | - | - |
FMX101 | Phase 3 | Acne Vulgaris | - | - |
FMX103 1.5% | Phase 3 | Papulopustular Rosacea | - | - |
FMX-101, 4% minocycline foam | Phase 3 | Acne Vulgaris | - | - |
Vehicle Foam | Phase 3 | Acne Vulgaris | - | - |
FMX103 minocycline foam 1.5% | Phase 3 | Facial Papulopustular Rosacea | - | - |
serlopitant | Phase 2 | Prurigo Nodularis | - | - |
5 mg Serlopitant Tablets | Phase 2 | Pruritus | - | - |
VYN201 Gel | Phase 2 | Non-segmental Vitiligo | - | - |
FMX114 | Phase 2 | Atopic Dermatitis | - | - |
Serlopitant High Dose | Phase 2 | Pruritus | - | - |
FMX-103 1.5% | Phase 2 | Rosacea | - | - |
3% Minocycline Foam | Phase 2 | Acne Vulgaris | - | - |
FDX104 (4% Doxycycline) | Phase 2 | Rash Due to Epidermal Growth Factor Receptor Inhibitors | - | - |
VPD-737 | Phase 2 | Chronic Pruritus | - | - |
MK0594 | Phase 2 | Urinary Incontinence | - | - |
Topical Minocycline Foam FXFM244 | Phase 2 | Acne Vulgaris | - | - |
Acne Vulgaris
5 drugs in this indication
Pruritus
5 drugs in this indication
Rash Due to Epidermal Growth Factor Receptor Inhibitors
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Chronic Pruritus
1 drug in this indication
Papulopustular Rosacea
1 drug in this indication
Rosacea
1 drug in this indication
Urinary Incontinence
1 drug in this indication
Facial Papulopustular Rosacea
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)